Yu, C., Shen, Q., Holmes, A. B., Mo, T., Tosato, A., Soni, R. K., Corinaldesi, C., Koul, S., Pasqualucci, L., Hussein, S., Forouhar, F., Dalla-Favera, R., & Basso, K. (2024). MEF2B C-terminal mutations enhance transcriptional activity and stability to drive B cell lymphomagenesis. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-51644-8

Kline, C., Crawford, J. R., Reddy, A. T., Gerber, N., Stucklin, A. G., Kilburn, L., Packer, R., Margol, A., Crotty, E., Sayour, E., Franson, A., Phillips, J., Singh, S., Hamanishi, E., Lee, C., Bhatia, A., George, E., Rauschecker, A., Molinaro, A., … Mueller, S. (2024). TRLS-07. PNOC016: INTRATUMORAL PHARMACOKINETICS AND PHARMACODYNAMIC (PK/PD) RESULTS FROM A TARGET VALIDATION STUDY OF A NOVEL PAN-HDAC AND PI3K INHIBITOR, FIMEPINOSTAT, IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG), RECURRENT MEDULLOBLASTOMA (MB), AND RECURRENT HIGH-GRADE GLIOMA (HGG). Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.160

Cheng, K., Seita, Y., Whelan, E. C., Yokomizo, R., Hwang, Y. S., Rotolo, A., Krantz, I. D., Ginsberg, J. P., Kolon, T. F., Lal, P., Luo, X., Pierorazio, P. M., Linn, R. L., Ryeom, S., & Sasaki, K. (2024). Defining the cellular origin of seminoma by transcriptional and epigenetic mapping to the normal human germline. Cell Reports, 43(6), 114323. https://doi.org/10.1016/j.celrep.2024.114323

Watanabe, J., Clutter, M. R., Gullette, M. J., Sasaki, T., Uchida, E., Kaur, S., Mo, Y., Abe, K., Ishi, Y., Takata, N., Natsumeda, M., Gadd, S., Zhang, Z., Becher, O. J., & Hashizume, R. (2024). BET bromodomain inhibition potentiates radiosensitivity in models of H3K27-altered diffuse midline glioma. Journal of Clinical Investigation, 134(13). https://doi.org/10.1172/jci174794

Mellgard, G., Gilligan, M., Cliff, E. R. S., Bhutani, D., Mohyuddin, G. R., Eisenberger, A., Lentzsch, S., & Chakraborty, R. (2024). Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma. HemaSphere, 8(3). Portico. https://doi.org/10.1002/hem3.61

Schöffski, P., Lorusso, P., Yamamoto, N., Reichardt, P., Schwartz, L., Dercle, L., Zhao, B., Chitalia, R., Montgomery, G., Hu, C., Landsteiner, H. T., Jayadeva, G., & Gounder, M. (2024). 56O A phase Ia/Ib study of the MDM2-p53 antagonist brigimadlin (BI 907828): Safety and efficacy in patients with dedifferentiated liposarcoma. ESMO Open, 9, 102446. https://doi.org/10.1016/j.esmoop.2024.102446

Xiao, M., Kondo, S., Nomura, M., Kato, S., Nishimura, K., Zang, W., Zhang, Y., Akashi, T., Viny, A., Shigehiro, T., Ikawa, T., Yamazaki, H., Fukumoto, M., Tanaka, A., Hayashi, Y., Koike, Y., Aoyama, Y., Ito, H., Nishikawa, H., … Inoue, D. (2023). BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin state. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-44081-6

Daver, N., Zeidner, J. F., Yuda, J., Watts, J. M., Levis, M. J., Fukushima, K., Ikezoe, T., Ogawa, Y., Brandwein, J., Wang, E. S., Miyazaki, Y., Pardee, T., Hosono, N., Shima, T., Yokoyama, H., Asada, N., Jurcic, J., Cai, H., Watanabe, A., … Erba, H. P. (2023). Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia. Blood, 142(Supplement 1), 2911–2911. https://doi.org/10.1182/blood-2023-179252

Mohan, M., Shah, N., Luan, D., Monge, J., Forsberg, M., Bhatlapenumarthi, V., Balev, M., Patwari, A., Cheruvalath, H., Bhutani, D., Thanendrarajan, S., Dhakal, B., Zangari, M., Al Hadidi, S., Cooper, D. L., Lentzsch, S., van Rhee, F., D’Souza, A., Szabo, A., … Chakraborty, R. (2023). Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study. Blood, 142(Supplement 1), 545–545. https://doi.org/10.1182/blood-2023-174875

Najjar, M., McCarron, J., Cliff, E. R. S., Berger, K., Steensma, D. P., Al Hadidi, S., Chakraborty, R., Goodman, A., Anto, E., Greene, T., Sborov, D., & Mohyuddin, G. R. (2023). Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma. JAMA Network Open, 6(11), e2342195. https://doi.org/10.1001/jamanetworkopen.2023.42195

Dhodapkar, M. V., Alsina, M., Berdeja, J. G., Patel, K. K., Richard, S., Vij, R., Leleu, X., Egan, D. N., Bergsagel, P. L., Reshef, R., Usmani, S. Z., Truppel-Hartmann, A., Basudhar, D., Thompson, E., Zheng, X., Eliason, L., Zhong, X., Greggio, C., Tran, S., … Siegel, D. S. (2023). Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up. Blood, 142(Supplement 1), 2101–2101. https://doi.org/10.1182/blood-2023-173970

Biran, N., Dhakal, B., Niesvizky, R., Lentzsch, S., McKay, J. T., Vesole, D. H., Nooka, A. K., Paul, B., Hari, P. N., Stork-Sloots, L., D’Ambrosi, S., Kuiper, R., van Vliet, M., Siegel, D. S., Usmani, S. Z., & van Rhee, F. (2023). Prommis Trial Prospectively Demonstrates the Efficacy of SKY92 Risk Stratification in Newly Diagnosed Multiple Myeloma Patients. Blood, 142(Supplement 1), 3386–3386. https://doi.org/10.1182/blood-2023-180761

Xu, J. J., Chen, Y., Pantazi, J., Fernando, S., Alija, B., Sudunagunta, V., Bhagat, G., Bowman, R. L., & Viny, A. D. (2023). Stag2-Cohesin Loss Attenuates Flt3 ITD Myeloid Blast Expansion Yet Preserves Mutant HSC. Blood, 142(Supplement 1), 2756–2756. https://doi.org/10.1182/blood-2023-190702

Biran, N., Dhakal, B., Niesvizky, R., Lentzsch, S., McKay, J. T., Vesole, D. H., Nooka, A. K., Paul, B., Hari, P. N., Stork-Sloots, L., D’Ambrosi, S., Kuiper, R., van Vliet, M., Siegel, D. S., Usmani, S. Z., & van Rhee, F. (2023). Unveiling the Discrepancy in Multiple Myeloma Risk Classification between Clinical Practice and SKY92 Test and the Impact on Survival. Blood, 142(Supplement 1), 2013–2013. https://doi.org/10.1182/blood-2023-181905

Mohyuddin, G. R., Chakraborty, R., Cliff, E. R. S., & Derman, B. A. (2023). Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey. EClinicalMedicine, 65, 102272. https://doi.org/10.1016/j.eclinm.2023.102272

Zhou, N., Choi, J., Grothusen, G., Kim, B.-J., Ren, D., Cao, Z., Liu, Y., Li, Q., Inamdar, A., Beer, T., Tang, H.-Y., Perkey, E., Maillard, I., Bonasio, R., Shi, J., Ruella, M., Wan, L., & Busino, L. (2023). DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance. Blood, 142(11), 973–988. https://doi.org/10.1182/blood.2022018752

Li, S., Fu, J., Liu, G., Ma, H., Mapara, M., Marcireau, C., & Lentzsch, S. (2023). P-200 MAP4K2 inhibition reinforces sensitivity to iberdomide in RAS-mutated MM through a CRBN-independent mechanism. Clinical Lymphoma Myeloma and Leukemia, 23, S145–S146. https://doi.org/10.1016/s2152-2650(23)01818-9

Chakraborty, R., Al Hadidi, S., Scheffer Cliff, E. R., & Mohyuddin, G. R. (2023). Is aggressive treatment of smoldering myeloma the path to curing myeloma? Blood Advances, 7(15), 3932–3935. https://doi.org/10.1182/bloodadvances.2023009658

Lee, H. C., Bumma, N., Richter, J., Dhodapkar, M., Hoffman, J. E., Suvannasankha, A., Zonder, J., Shah, M. R., Lentzsch, S., Maly, J. J., Ye, J. C., Wu, K. L., Deveaux, M., Chokshi, D., Boyapati, A., Hazra, A., Lorenc, K. R., Kroog, G., Houvras, Y., & Jagannath, S. (2023). S197: LINKER-MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. HemaSphere, 7(S3), e1610068. https://doi.org/10.1097/01.hs9.0000967700.16100.68

Ferhat, A.-T., Verpy, E., Biton, A., Forget, B., De Chaumont, F., Mueller, F., Le Sourd, A.-M., Coqueran, S., Schmitt, J., Rochefort, C., Rondi-Reig, L., Leboucher, A., Boland, A., Fin, B., Deleuze, J.-F., Boeckers, T. M., Ey, E., & Bourgeron, T. (2023). Excessive self-grooming, gene dysregulation and imbalance between the striosome and matrix compartments in the striatum of Shank3 mutant mice. Frontiers in Molecular Neuroscience, 16. https://doi.org/10.3389/fnmol.2023.1139118

Vasciaveo, A., Arriaga, J. M., de Almeida, F. N., Zou, M., Douglass, E. F., Picech, F., Shibata, M., Rodriguez-Calero, A., de Brot, S., Mitrofanova, A., Chua, C. W., Karan, C., Realubit, R., Pampou, S., Kim, J. Y., Afari, S. N., Mukhammadov, T., Zanella, L., Corey, E., … Abate-Shen, C. (2022). OncoLoop: A Network-Based Precision Cancer Medicine Framework. Cancer Discovery, 13(2), 386–409. https://doi.org/10.1158/2159-8290.cd-22-0342

Li, S., Fu, J., Yang, J., Ma, H., Mapara, M. Y., Marcireau, C., & Lentzsch, S. (2022). MAP4K2 Inhibition Reinforces the Iberdomide Sensitivity in MM Cells By Inducing IKZF1 Degradation through a CRBN Independent Mechanism. Blood, 140(Supplement 1), 4224–4225. https://doi.org/10.1182/blood-2022-168314

Batlevi, C. L., Salles, G., Park, S. I., Phillips, T. J., Amengual, J. E., Andorsky, D., Campbell, P., McKay, P., Leonard, J. P., Sondhi, M., Chen, Y., Slatcher, P. L., Lin, R., Szanto, A., Abbadi, S., & Morschhauser, F. (2022). Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1. Blood, 140(Supplement 1), 2296–2298. https://doi.org/10.1182/blood-2022-166991

Baljevic, M., Gasparetto, C., Schiller, G. J., Tuchman, S. A., Callander, N. S., Lentzsch, S., Monge, J., Kotb, R., Bahlis, N. J., White, D., Chen, C. I., Sutherland, H. J., Madan, S., LeBlanc, R., Sebag, M., Venner, C. P., Bensinger, W. I., Biran, N., DeCastro, A., … Lipe, B. (2022). Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment. EJHaem, 3(4), 1270–1276. Portico. https://doi.org/10.1002/jha2.572

Laise, P., Bosker, G., Califano, A., & Alvarez, M. J. (2022). A Patient‐to‐Model‐to‐Patient (PMP) Cancer Drug Discovery Protocol for Identifying and Validating Therapeutic Agents Targeting Tumor Regulatory Architecture. Current Protocols, 2(9). Portico. https://doi.org/10.1002/cpz1.544

Sato, T., Ikeguchi, A. P., Nathan, P., Carvajal, R. D., Shoushtari, A. N., Gajewski, T. F., Hassel, J. C., Rioth, M., Leyvraz, S., Daniels, G. A., Hernandez-Aya, L., Johnson, D. B., Kim, K., Piulats Rodriguez, J. M., Cowey, C. L., Lockwood, S., Collins, L., Karakuzu, O., Sacco, J. J., & Butler, M. O. (2022). 843P Long-term survivors on tebentafusp in phase II trial of previously treated patients with metastatic uveal melanoma. Annals of Oncology, 33, S934–S935. https://doi.org/10.1016/j.annonc.2022.07.969

Zhou, D., Wu, Z., Park, J.-G., Fiches, G. N., Li, T.-W., Ma, Q., Huang, H., Biswas, A., Martinez-Sobrido, L., Santoso, N. G., & Zhu, J. (2022). FACT subunit SUPT16H associates with BRD4 and contributes to silencing of interferon signaling. Nucleic Acids Research, 50(15), 8700–8718. https://doi.org/10.1093/nar/gkac645

Gounder, M. M., Razak, A. A., Somaiah, N., Chawla, S., Martin-Broto, J., Grignani, G., Schuetze, S. M., Vincenzi, B., Wagner, A. J., Chmielowski, B., Jones, R. L., Riedel, R. F., Stacchiotti, S., Loggers, E. T., Ganjoo, K. N., Le Cesne, A., Italiano, A., Garcia del Muro, X., Burgess, M., … Attia, S. (2022). Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Oncology, 40(22), 2479–2490. https://doi.org/10.1200/jco.21.01829

Zonder, J. A., Richter, J., Bumma, N., Brayer, J., Hoffman, J. E., Bensinger, W. I., Wu, K. L., Xu, L., Chokshi, D., Boyapati, A., Cronier, D., Houvras, Y., Rodriguez Lorenc, K., Kroog, G. S., Dhodapkar, M. V., Lentzsch, S., Cooper, D., & Jagannath, S. (2022). S189: EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CRS WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST-IN-HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. HemaSphere, 6, 90–91. https://doi.org/10.1097/01.hs9.0000843648.44771.79

Zacharoulis, S., Szalontay, L., CreveCoeur, T., Neira, J., Higgins, D., Englander, Z., Spinazzi, E., Sethi, C., Canoll, P., Garvin, J., Zylber, R., Damment, S., Zamoryakhin, D., Maddocks, A., Feldstein, N., & Bruce, J. (2022). DDEL-07. A Phase I study examining the feasibility of intermittent convection-enhanced delivery (CED) of MTX110 for the treatment of children with newly diagnosed diffuse midline gliomas (DMGs). Neuro-Oncology, 24(Supplement_1), i35–i35. https://doi.org/10.1093/neuonc/noac079.128